Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is garnering increased attention from analysts as it approaches critical milestones in its drug development pipeline. The biopharmaceutical company, focused on treatments for obesity and chronic myeloid leukemia (CML), has seen its stock price fluctuate in recent months as investors anticipate key data releases.
TERN-601: A Potential Game-Changer in Obesity Treatment
Terns Pharmaceuticals' lead candidate for obesity treatment, TERN-601, has shown promising results in its Phase 1 clinical trial. The oral GLP-1 receptor agonist demonstrated a -4.9% placebo-adjusted weight loss over 28 days at the highest dose tested (740 mg). This efficacy is considered competitive within the oral obesity treatment field, positioning TERN-601 as a potential contender in the growing market for weight loss medications.
The dose-dependent weight loss exhibited a near-linear decline, suggesting the possibility of continued efficacy at various dosages. This characteristic could provide flexibility in treatment regimens, potentially addressing different patient needs.
Tolerability of TERN-601 was in line with expectations, with no severe adverse events or discontinuations during the study. Most adverse events were gastrointestinal-related, with nausea being the most common but manageable symptom. The company is preparing to advance rapidly to a 12-week Phase 2a clinical trial if the Phase 1 results continue to be supportive.
TERN-701: Targeting the CML Market
In the oncology space, Terns Pharmaceuticals is developing TERN-701, a third-generation allosteric tyrosine kinase inhibitor (TKI) for the treatment of chronic myeloid leukemia. The ongoing CARDINAL trial is a global Phase 1 study assessing the safety, pharmacokinetics, and efficacy of TERN-701 in CML patients who have failed or had suboptimal responses to prior treatments.
Recent positive Phase 3 results from Novartis (SIX:NOVN)' Scemblix (asciminib), a similar drug in the CML space, have bolstered confidence in TERN-701's potential. Analysts believe that despite the presence of generic imatinib, there is a significant opportunity for TERN-701 in both second-line and potentially first-line CML treatment due to its differentiated profile, including no food effect and once-daily dosing.
Financial Position and Management Changes
Terns Pharmaceuticals reported a strong cash balance of $241 million as of the first quarter of 2024, providing a financial runway into 2026. This solid financial footing allows the company to continue its clinical development programs without immediate funding concerns.
The company has undergone recent management changes, including the departure of COO Bryan Yoon and CFO Mark Vignola, although the CFO will remain until 2025. Dr. Erin Quirk has also left her position, with responsibilities reassigned to other executives. These transitions are being closely monitored by investors for any potential impact on the company's operations and strategy.
Pipeline Developments and Future Prospects
While TERN-601 and TERN-701 are the company's primary focus, Terns Pharmaceuticals continues to advance its early pipeline. The development of TERN-501, an oral THR-β agonist, is currently paused pending partnership or future funding. Internal discovery efforts are ongoing for small molecule GIPR modulators for obesity, with an aim to nominate an internal GIPR drug candidate for combination therapy.
The company is planning to host a CML-focused Key Opinion Leader (KOL) event in mid-2024 to provide context for interpreting early CML datasets, setting the stage for anticipated data releases later in the year.
Bear Case
How might competition affect TERN-601's market potential?
The obesity treatment market is becoming increasingly crowded, with several established players and new entrants vying for market share. TERN-601 faces competition from both injectable GLP-1 receptor agonists, which have shown significant efficacy, and other oral treatments in development. Roche/Carmot's CT-996, for example, achieved a 6.1% placebo-adjusted weight loss at 28 days, setting a high benchmark for efficacy.
The success of TERN-601 will depend not only on its weight loss efficacy but also on its long-term safety profile and patient adherence. The high incidence of gastrointestinal side effects, although manageable, could potentially impact patient compliance and commercial viability. If competing drugs demonstrate superior efficacy or tolerability, TERN-601 may struggle to capture significant market share, potentially limiting Terns Pharmaceuticals' revenue potential in this space.
What risks does TERN face in its clinical trials?
Clinical trial outcomes are inherently uncertain, and Terns Pharmaceuticals faces several risks as it advances its pipeline. For TERN-601, the transition from Phase 1 to Phase 2a trials introduces new challenges. The longer duration of the 12-week Phase 2a trial may reveal safety concerns or diminished efficacy not apparent in the shorter Phase 1 study. Additionally, the rapid titration used in Phase 1 may have contributed to higher adverse events, and adjustments to the dosing schedule in Phase 2 could impact the drug's efficacy profile.
For TERN-701, the competitive landscape in CML treatment is evolving rapidly. The success of Novartis' Scemblix sets a high bar for efficacy and safety that TERN-701 must meet or exceed to be commercially viable. Any setbacks in the CARDINAL trial, such as unexpected adverse events or suboptimal efficacy, could significantly impact the company's valuation and future prospects in the oncology market.
Bull Case
How could positive TERN-601 data impact Terns Pharmaceuticals' valuation?
Positive data from the TERN-601 trials could significantly boost Terns Pharmaceuticals' valuation. The obesity treatment market is projected to grow substantially in the coming years, driven by increasing prevalence of obesity and demand for effective, convenient treatments. If TERN-601 demonstrates efficacy comparable to or better than existing oral treatments, particularly with a favorable safety profile, it could position Terns Pharmaceuticals as a major player in this lucrative market.
Analysts have outlined potential scenarios for TERN-601's impact on the stock price. A best-in-class weight loss outcome of 6% could lead to a stock increase of approximately 62%, while good weight loss data in the 4%-5% range could result in a 27% increase. These projections highlight the significant upside potential if TERN-601 meets or exceeds expectations in upcoming trials.
What advantages does TERN-701 offer in the CML market?
TERN-701's potential in the CML market is bolstered by several factors. As a third-generation allosteric tyrosine kinase inhibitor, it offers a differentiated mechanism of action compared to earlier treatments. The drug's convenient once-daily dosing and lack of food effect could provide significant quality-of-life improvements for patients, potentially driving adoption and compliance.
The success of Novartis' Scemblix, which is projected to reach revenues of $3 billion, demonstrates the substantial market opportunity for innovative CML treatments. If TERN-701 can show comparable or superior efficacy and safety profiles, it could capture a significant portion of this market. Additionally, its potential use in both second-line and first-line CML treatment expands its addressable patient population, further increasing its commercial potential.
SWOT Analysis
Strengths:
- Strong cash position providing runway into 2026
- Promising early clinical data for TERN-601 in obesity treatment
- Differentiated profile of TERN-701 for CML treatment
- Diverse pipeline addressing large market opportunities
Weaknesses:
- Recent management changes may lead to transitional challenges
- Paused development of TERN-501 due to funding constraints
- Reliance on success of two main drug candidates
Opportunities:
- Large and growing markets in obesity and CML treatment
- Potential for TERN-601 to compete effectively in the oral obesity treatment space
- Possibility of TERN-701 capturing market share in both second-line and first-line CML treatment
Threats:
- Strong competition in both obesity and CML markets
- Regulatory risks and uncertainties in drug approval process
- Potential for clinical trial setbacks or unfavorable data
Analysts Targets
- JMP Securities: $20 (September 10th, 2024)
- JMP Securities: $15 (September 3rd, 2024)
- JMP Securities: $15 (August 7th, 2024)
- BMO Capital Markets: $19 (May 14th, 2024)
Terns Pharmaceuticals stands at a critical juncture as it approaches key data readouts for its lead drug candidates. The company's ability to deliver positive clinical results and navigate the competitive landscape will be crucial in determining its future success and market position. Investors and analysts will be closely watching the upcoming data releases and regulatory milestones as indicators of the company's long-term potential in the biopharmaceutical industry.
This analysis is based on information available up to September 30, 2024.
InvestingPro: Smarter Decisions, Better Returns
Gain an edge in your investment decisions with InvestingPro’s in-depth analysis and exclusive insights on TERN. Our Pro platform offers fair value estimates, performance predictions, and risk assessments, along with additional tips and expert analysis. Explore TERN’s full potential at InvestingPro.
Should you invest in TERN right now? Consider this first:
Investing.com’s ProPicks, an AI-driven service trusted by over 130,000 paying members globally, provides easy-to-follow model portfolios designed for wealth accumulation. Curious if TERN is one of these AI-selected gems? Check out our ProPicks platform to find out and take your investment strategy to the next level.
To evaluate TERN further, use InvestingPro’s Fair Value tool for a comprehensive valuation based on various factors. You can also see if TERN appears on our undervalued or overvalued stock lists.
These tools provide a clearer picture of investment opportunities, enabling more informed decisions about where to allocate your funds.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.